On the public citation graph
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis
0 signed · 61 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamacardio.2020.4511openalex-snapshot
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.1001/jamanetworkopen.2021.6139openalex-snapshot
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
inferredcites →https://doi.org/10.1002/pds.677openalex-snapshot
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
inferredcites →https://doi.org/10.1002/sim.3247openalex-snapshot
A statistical methodology for drug–drug interaction surveillance
inferredcites →https://doi.org/10.1007/s00228-014-1658-1openalex-snapshot
Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
inferredcites →https://doi.org/10.1007/s13300-018-0408-2openalex-snapshot
Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
inferredcites →https://doi.org/10.1007/s40262-013-0128-8openalex-snapshot
Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1007/s40264-022-01166-3openalex-snapshot
Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data
inferredcites →https://doi.org/10.1007/s40264-022-01191-2openalex-snapshot
Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"
inferredcites →https://doi.org/10.1016/j.cjca.2019.11.036openalex-snapshot
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
inferredcites →https://doi.org/10.1016/j.cpcardiol.2020.100765openalex-snapshot
Myopathy Associated With Statins and SGLT2 – A Review of Literature
inferredcites →https://doi.org/10.1016/j.jacc.2018.01.085openalex-snapshot
SGLT-2 Inhibitors and Cardiovascular Risk
inferredcites →https://doi.org/10.1016/j.jacc.2018.03.009openalex-snapshot
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
inferredcites →https://doi.org/10.1016/j.numecd.2018.02.014openalex-snapshot
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
inferredcites →https://doi.org/10.1046/j.1532-5415.2002.50017.xopenalex-snapshot
Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients
inferredcites →https://doi.org/10.1080/17425255.2021.1921735openalex-snapshot
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
inferredcites →https://doi.org/10.1093/bib/bbab347openalex-snapshot
Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source
inferredcites →https://doi.org/10.1097/01.ccm.0000528447.29915.42openalex-snapshot
429: RHABDOMYOLYSIS SECONDARY TO DIABETIC KETOACIDOSIS
inferredcites →https://doi.org/10.1111/bcp.15178openalex-snapshot
Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors
inferredcites →https://doi.org/10.1111/bph.13882openalex-snapshot
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
inferredcites →https://doi.org/10.1111/j.1365-2125.2007.02900.xopenalex-snapshot
Detecting signals of drug–drug interactions in a spontaneous reports database
inferredcites →https://doi.org/10.1111/j.1365-2125.2008.03176.xopenalex-snapshot
A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding
inferredcites →https://doi.org/10.1161/jaha.120.019463openalex-snapshot
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
inferredcites →https://doi.org/10.1517/14740338.6.4.451openalex-snapshot
Signal detection methodologies to support effective safety management
inferredcites →https://doi.org/10.1530/edm-20-0017openalex-snapshot
Myopathy secondary to empagliflozin therapy in type 2 diabetes
inferredcites →https://doi.org/10.2165/00002018-199920020-00002openalex-snapshot
The Medical Dictionary for Regulatory Activities (MedDRA)
inferredcites →https://doi.org/10.2337/dc17-2280openalex-snapshot
Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
inferredcites →https://doi.org/10.2337/dc21-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
inferredcites →https://doi.org/10.2337/dc22-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
inferredcites →https://doi.org/10.3389/fphar.2019.01319openalex-snapshot
Review of Statistical Methodologies for Detecting Drug–Drug Interactions Using Spontaneous Reporting Systems
inferredcites →https://doi.org/10.3390/pharmaceutics13101531openalex-snapshot
Verification of the “Upward Variation in the Reporting Odds Ratio Scores” to Detect the Signals of Drug–Drug Interactions
inferredcites →https://doi.org/10.4212/cjhp.v75i2.3066openalex-snapshot
Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors
inferredcites →https://doi.org/10.7326/l20-0549openalex-snapshot
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report
inferredcites →https://doi.org/10.7326/m20-0289openalex-snapshot
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
inferredcites →https://doi.org/10.9734/bjmmr/2017/33253openalex-snapshot
Marked Weight Loss, Muscle Wasting and Fatigue on Administration of Empagliflozin in a Subject with Type 2 Diabetes
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4832604openalex-extracted
Medication -Induced Rhabdomyolysis: A Disproportionality Analysis of the FAERS Data
inferred← citeshttps://doi.org/10.1007/s00228-024-03779-2openalex-snapshot
Association between sodium-glucose cotransporter-2 inhibitor and adverse events in patients with moderate to severe chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00592-025-02550-yopenalex-snapshot
Drugs used in diabetes, statins and the risk of rhabdomyolysis reporting: a disproportionality analysis in the world health organization’s pharmacovigilance database
inferred← citeshttps://doi.org/10.1007/s11096-024-01804-zopenalex-snapshot
Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s11560-024-00790-7openalex-snapshot
Statininduzierte Rhabdomyolyse in Zusammenhang mit neu begonnener SGLT2-Inhibitor-Therapie
inferred← citeshttps://doi.org/10.1007/s12012-026-10174-zopenalex-snapshot
QT Prolongation, Ventricular Arrhythmia, and Cardiac Arrest Signals During Ceftriaxone Co-therapy with Individual Proton Pump Inhibitors: A Multidatabase Study
inferred← citeshttps://doi.org/10.1007/s40263-025-01230-3openalex-snapshot
Sodium–Glucose Cotransporter 2 Inhibitors: An Emerging Therapeutic Approach for Ischemic Stroke Management
inferred← citeshttps://doi.org/10.1007/s40264-024-01433-5openalex-snapshot
Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis
inferred← citeshttps://doi.org/10.1007/s40267-026-01268-3openalex-snapshot
Personalize statin therapy following acute ischemic stroke
inferred← citeshttps://doi.org/10.1016/j.ajpc.2025.101061openalex-snapshot
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
inferred← citeshttps://doi.org/10.1016/j.ejim.2025.07.016openalex-snapshot
Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle
inferred← citeshttps://doi.org/10.1080/14740338.2024.2376693openalex-snapshot
Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1111/bcp.15780openalex-snapshot
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice
inferred← citeshttps://doi.org/10.1111/bcp.15802openalex-snapshot
Considerations on the use of different comparators in pharmacovigilance: A methodological review
inferred← citeshttps://doi.org/10.1111/joim.70062openalex-snapshot
Risk of rhabdomyolysis with concomitant use of statins and SGLT2 inhibitors: A population‐based cohort study
inferred← citeshttps://doi.org/10.1186/s12872-023-03353-1openalex-snapshot
SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI
inferred← citeshttps://doi.org/10.1186/s12933-025-02777-7openalex-snapshot
Impact of sodium–glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review
inferred← citeshttps://doi.org/10.2196/preprints.78421openalex-snapshot
Cardiovascular Event Risk Among Individuals Treated with Ceftriaxone and Proton Pump Inhibitors: Evidence from Multi-Database Studies (Preprint)
inferred← citeshttps://doi.org/10.25259/ijn_25_2024openalex-snapshot
Severe Rhabdomyolysis Due to Presumed Drug Interactions of Dapagliflozin with Rosuvastatin: A Case Report
inferred← citeshttps://doi.org/10.3389/fphar.2024.1372401openalex-snapshot
Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
inferred← citeshttps://doi.org/10.3389/fphar.2024.1445324openalex-snapshot
Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug–drug interactions through the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.3390/diabetology7060108openalex-snapshot
Drug–Drug and Drug–Disease Interactions Across Antidiabetic Drug Classes: A Narrative Review and Practical Recommendations
inferred← citeshttps://doi.org/10.3390/jcm14030882openalex-snapshot
Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation
inferred← citeshttps://doi.org/10.5005/jp-journals-11006-0118openalex-snapshot
Drug-induced Rhabdomyolysis, Acute Interstitial Nephritis, and Acute Kidney Injury: A Case Report
inferred← citeshttps://doi.org/10.7759/cureus.95693openalex-snapshot
Severe Rhabdomyolysis in an Elderly Patient With Diabetes and Vascular Disease: Interplay of Statin Therapy, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibition, and Thiazide-Induced Hypokalemia
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.